



**LEARNING TO LIVE  
WITH CORONAVIRUSES?**

**JOSEPH MCCORMICK, MD**



**SUSAN FISHER-HOCH, MD**

**Professors of Epidemiology  
Brownsville Campus**

**UTHealth School of Public Health**

# Hot spots


January 2022



# WHO data. Worldwide reports as of January 2022


## 340,543,962

confirmed cases



## 5,570,163

deaths



Source: World Health Organization

▨ Data may be incomplete for the current day or week.

# **WARNING**

**Local, national and global data are subject to major reporting artefacts.**

**Poor and remote communities are not tested**

**People do not come forward for testing**

**Home testing and other kits and sites do not report**

**Testing will miss most of the asymptomatic cases**

**Testing misses people who die at home or elsewhere**

# Greek alphabet

Αα	Alpha	Νν	Nu
Ββ	Beta	Ξξ	Xi
Γγ	Gamma	Οο	Omicron
Δδ	Delta	Ππ	Pi
Εε	Epsilon	Ρρ	Rho
Ζζ	Zeta	Σσς	Sigma
Ηη	Eta	Ττ	Tau
Θθ	Theta	Υυ	Upsilon
Ιι	Iota	Φφ	Phi
Κκ	Kappa	Χχ	Chi
Λλ	Lambda	Ψψ	Psi
Μμ	Mu	Ωω	Omega


## The variants!!!

Time to learn your Greek alphabet

**Variants of concern (VOC)**

**Variants of interest (VOI)**

Delta




## Variants of Concern (VOC) January 11 2022

Proportion of VOC among total sequences  
(countries with  $\geq 100$  sequences in last 30 days)\*


- 0.501 - 1.000
- 0.101 - 0.500
- 0.011 - 0.100
- >0.000 - 0.010
- VOC detected, proportion not estimated\*\*
- No presence of VOC reported

Omicron




# Cases, hospitalizations and deaths in US comparing Delta and Omicron waves

● Cases ● Deaths ● Hospitalizations




# Despite differences in testing and surveillance marked case increases occurred in each area with Omicron

Africa   Asia-Pacific   Europe   Latin America   Middle East   U.S. and Canada





# Reported cases per day from Omicron in the US are more than double that of Jan. 2021 peak




# Omicron is associated with marked increase in testing, cases reported, hospitalizations and deaths in the US


## U.S. trends

All time Last 90 days


New reported cases by day




Hospitalizations



Tests by day




New reported deaths by day



# All age groups experienced sharp increases in hospitalizations from Omicron including children


## Daily new hospital admissions by age

This chart shows for each age group the number of people per 100,000 that were newly admitted to a hospital with Covid-19 each day, according to data reported by hospitals to the U.S. Department of Health and Human Services.





About this data

## Sequence of events in SARS-COV2 infection and virus clearance



# Comparison of incubation and infectious periods for delta and omicron variants



**Table 2: Summary of phenotypic impacts\* of variants of concern**

WHO label	Alpha	Beta	Gamma	Delta	Omicron
<b>Transmissibility</b>	Increased transmissibility <sup>12</sup>	Increased transmissibility <sup>13,14</sup>	Increased transmissibility <sup>14,15</sup>	Increased transmissibility <sup>14,16,17</sup>	Increased transmissibility. <sup>1-4</sup>
<b>Disease severity</b>	Possible increased risk of hospitalization <sup>18,19</sup> , possible increased risk of severe disease and death <sup>20,21</sup>	Possible increased risk of hospitalization <sup>19</sup> , possible increased in-hospital mortality <sup>22</sup>	Possible increased risk of hospitalization <sup>19</sup> , possible increased risk of severe disease <sup>23</sup>	Possible increased risk of hospitalization <sup>24,25</sup>	Possible reduced risk of hospitalization and severe disease <sup>5-8</sup>
<b>Risk of reinfection</b>	Neutralizing activity retained <sup>26</sup> , risk of reinfection remains similar <sup>27</sup>	Reduction in neutralizing activity reported; T cell response elicited by D614G virus remains effective <sup>28</sup>	Moderate reduction in neutralizing activity reported <sup>29</sup>	Reduction in neutralizing activity reported <sup>30-32</sup>	Increased risk of reinfection <sup>11,33</sup>
<b>Impacts on diagnostics</b>	Limited impact – S gene target failure (SGTF), no impact on overall result from multiple target RT-PCR; No impact on Ag RDTs observed <sup>34</sup>	No impact on RT-PCR or Ag RDTs observed <sup>32</sup>	None reported to date	No impact on RT-PCR or Ag RDTs observed <sup>35</sup>	PCR continues to detect Omicron. Impact on Ag-RDTs is under investigation: Results are mixed as to whether or not there may be decreased sensitivity to detect Omicron. <sup>1,8,36-38</sup>

\*Generalized findings as compared to previously/co-circulating variants. Based on emerging evidence, including non-peer-reviewed preprint articles and reports, all subject to ongoing investigation and revision.



Number of mutations identified in each variant's spike, date of earliest documented sample


### A look at the spike

Every spike on a coronavirus's surface is made of three identical proteins twisted together, making it look a little like a head of broccoli with three stalks.

Each stalk has three vital regions — the receptor binding domain (RBD), the N-terminal domain (NTD) and the furin cleavage site (FCS) — and most of omicron's mutations are in these three areas.

<https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid/>

# Time to take a closer look at the famous spike







# Delta, Kappa: The B.1.617 Lineage



**B.1.617** carries more than a dozen mutations, but is sometimes called a “double mutant” because of two prominent mutations: **E484Q** and **L452R**.

The B.1.617 lineage has continued to evolve, splitting into new lineages including **B.1.617.1**, known as **Kappa**, and **B.1.617.2**, known as **Delta**. It has emerged as a fast-growing virus, [outpacing other variants of concern](#).



**E484Q** lies at the same location as **E484K**, the “Eek” mutation that might help the virus [evade some types of antibodies](#).


# The Omicron variant is a new lineage



Omicron's spike protein has several mutations that are found in other variants of concern and that are thought to make the virus more infectious, including [D614G](#), [N501Y](#) and [K417N](#).

# TRANSMISSIBILITY

The receptor binding site which acts like a key to open the cell to the virus




Notable mutations in this area




# IMMUNITY

**The N-terminal domain  
which is recognized by the  
immune system**




Notable mutations in this area




# SEVERE ILLNESS

**The furin cleavage site which allows the virus to spread from cell to cell**



Notable mutations in this area



## **What viral factors lead to new variants?**

- **Very high rate of infection which means billions and trillions of new virus replication events**
- **A virus may make multiple errors each time it replicates**
- **Most of these either make no difference or are fatal to the virus**
- **But multiply that by billions and trillions and variants with new or different properties emerge**
- **A very few give the virus an advantage. These are the ones that then overtake the others**

**THIS IS EVOLUTION FAST FORWARD**

## **WHAT ARE THE HUMAN FACTORS DRIVING MUTATIONS AND THEIR SPREAD?**

- **High rates of infection in unvaccinated individuals**
- **Vaccine refusal**
- **High rates of infection in crowded and disadvantaged places**
- **Uncontrolled large gatherings**
- **Failure to wear masks (correct masks worn correctly) in crowded and poorly ventilated settings**
- **Persistence of virus in the immunosuppressed (e.g. HIV)**















**The Ganges Festival  
January 2022**



# VACCINES

## Leading vaccines

Developer	How It Works	Phase	Status
 Pfizer-BioNTech	mRNA	<b>2</b> <b>3</b>	Approved in several countries. Emergency use in U.S., E.U., other countries.
 Moderna	mRNA	<b>3</b>	Approved in Switzerland. Emergency use in U.S., E.U., other countries.
 Gamaleya	Ad26, Ad5	<b>3</b>	Emergency use in Russia, other countries.
 Oxford-AstraZeneca	ChAdOx1	<b>2</b> <b>3</b>	Approved in Brazil. Emergency use in U.K., E.U., other countries.
 CanSino	Ad5	<b>3</b>	Approved in China. Emergency use in other countries.
 Johnson & Johnson	Ad26	<b>3</b>	Emergency use in U.S., E.U., other countries.
 Vector Institute	Protein	<b>3</b>	Early use in Russia. Approved in Turkmenistan.
 Novavax	Protein	<b>3</b>	*
 Sinopharm	Inactivated	<b>3</b>	Approved in China, U.A.E., Bahrain. Emergency use in other countries.
 Sinovac	Inactivated	<b>3</b>	Approved in China. Emergency use in other countries.
 Sinopharm-Wuhan	Inactivated	<b>3</b>	Approved in China. Limited use in U.A.E.
 Bharat Biotech	Inactivated	<b>3</b>	Emergency use in India, other countries.


\*Novavax protein nanoparticle vaccine is approved in the EU for 18 and above, Indonesia and Philippines, and EUA requested in the US. Stored 6 months at 4°C. These and similar low-cost, temperature stable vaccines need to be widely available in developing countries.



**DNA viruses: Herpes, CMV, smallpox, adenoviruses, chickenpox**

**Negative Strand RNA viruses: HIV, Polio, Influenza, Ebola, measles, mumps,**

**Positive Strand RNA viruses: SARS-CoV-2, Dengue, west Nile, Zika, rhinoviruses, rubella**



# mRNA history

**Dr. Katalin Karikó  
and Dr. Drew Weissmann**




## **1998 Penn State department of Medicine**

**Dr. Karikó was obsessed with MRNA but unfunded and marginalized but believed that it could coerce a cell into producing any kind of protein as long as you had the genetic code.**

**Dr Weissmann was physician and virologist.**

**However, injected mRNA was highly toxic and destroyed by cells**

**Together they worked out that natural mRNA was protected with a particular molecule.**



**Electron microscopy  
image of mRNA in a cell**

**THIS WAS THE BREAKTHROUGH THAT PRODUCED INJECTABLE mRNA**


**2013-2019**



**Working with the MERS virus Dr. Ian McLellan along with Dr. Barney Graham worked out where to put stabilizing mutations on the coronavirus spike.**



**This was a crucial step in elucidating the structure of the spike allowing the mRNA molecules to synthesize stable spikes.**




**2014**

**To protect the mRNA for injection a Canadian team, led by Dr. Collis, developed the lipid wrapping to preserve the structure as it entered the body**


# Daily Case and Death rates in vaccinated and unvaccinated in the US

Average daily cases




[About this data](#)

Average daily deaths




# Vaccination rates by age group and geographic areas US

## United States vaccinations




\*The C.D.C. reported on Nov. 30, 2021 that booster doses are sometimes misclassified as first doses, which may overestimate first dose coverage among adults.

Sources: Centers for Disease Control and Prevention, U.S. Census Bureau | Note: Figures include the U.S. territories and three countries with special agreements.




Texas

● Above U.S. share ● Below U.S. share



Sources: Centers for Disease Control and Prevention, U.S. Census Bureau


### When states will vaccinate 70% of adults at current rate



**West Virginia is off the map only achieving 70% in late October 2022**

## Daily reported doses given by manufacturer


Each line shows the seven-day average.



Source: Centers for Disease Control and Prevention

# New York City

100 Covid-19 hospitalizations per 100,000 people






# They both caught Covid, but one was vaccinated



**She got the shot. Her vaccine hesitant husband didn't.  
Now he's in a Mississippi ICU bed battling coronavirus.**



## *They Spurned the Vaccine. Now They Want You to Know They Regret It.*

People who once rejected the vaccine or simply waited too long are now grappling with the consequences, often in raw, public ways.

Glen Arnell, right, and Mindy Greene visited her husband, Russ Greene, at Utah Valley Specialty Hospital. Mr. Greene was hospitalized with complications from Covid-19 after choosing not to receive a vaccination for the virus. Kim Raff for The New York Times


# VIGNETTES




**New 32 year old unvaccinated mother dies from Covid-19 before she can hold her newborn**

**Quote from a father “My 16 month old son was lucky to get a pediatric ICU bed when he needed one for a non-COVID condition. He shouldn't have needed luck”**

# Effectiveness of Pfizer and Moderna vaccines against all COVID-19 over time




**Figure. Monthly Incidence Rates of Breakthrough SARS-CoV-2 Infections From July to November 2021 in 2 Cohorts**



**Fully vaccinated cohorts with two shots during the delta period**

## Greater risk of disease, hospitalization and death among unvaccinated vs. vaccinated people: National estimates



**At current incidence, 35,000 symptomatic infections per week among 162 million vaccinated Americans**

Data from COVID Tracker as of July 24, 2021. Average incidence 100 cases per 100,000 persons per week. Vaccine effectiveness against symptomatic illness = 88% (Lopez Bernal et al. [NEJM 2021](#)), where risk is  $[1 - VE]$  or 12%. Vaccine effectiveness hospitalization (or death) = 96% (Stowe et al. [PHE preprint](#)), where risk is  $[1 - VE]$  or 4%. Rate in unvaccinated = Community rate/ $[(1 - \text{fully vaccinated coverage}) + (1 - VE) * \text{fully vaccinated coverage}]$ . Rate in fully vaccinated =  $(1 - VE) * \text{Rate in unvaccinated}$ . Fully vaccinated coverage proportions were from COVID Data Tracker as of July 24, 2021 (50% for US).

## **EVIDENCE FOR EFFICACY OF BOOSTER SHOTS**

- **Improved protection in immunocompromised people.**
- **Vaccine breakthrough hospitalization more common with the Pfizer vaccine**
- **Protections from the Pfizer vaccine declined after 4 months from 2<sup>nd</sup> vaccine**
- **Higher antibody responses are seen from Moderna vaccine than Pfizer**
- **Differences in memory cell responses have not been assessed**
- **Complete evasion of antibody by Delta nor Omicron has not been demonstrated.**

**Overall conclusion is that vaccination with either vaccine reduced hospitalization, disease progression and likelihood of death**

## **CAN WE CREATE A UNIVERSAL VACCINE FOR ALL COVID-10 VARIANTS**

- **Research is in progress**
- **Current vaccines based on the original spike sequences may need further boosters**
- **Knowing which regions of the spike proteins are highly conserved but susceptible to antibodies might allow design of a universal SARS-CoV-2 vaccine for all variants**
- **The spike protein receptor binding domain also flips between up and down positions. Significance uncertain, but demonstration of plasticity of the virus**
- **Researchers who have used cryogenic electron microscope to visualize the two most potent antibodies, say that these skirt around locations lower on the tip where the mutation spots are found and avoid them. This seems to allow them to identify other sites which are highly conserved, not appreciably affected by variations in sequence.**



# Selected treatments including antivirals and anti inflammatory drugs

## FDA approved

**Paxlovid oral treatment reduces hospitalization and death by 88% if given within 5 days of onset.**

## EUA approved or widely used

**Evusheld (AZD7442) injectible antibodies 77% effective EUA**

**Molnupiravir antiviral about 30%**

**Ensovibep antiviral protein reduce 78%**

**Remdesivir**

**Baricitinib\* anti IL-6 arthritis EUA**

**Tocilizumab\* anti IL-6 arthritis EUA**

**\* With dexamethasone**

## Not Promising

**Ivermectin**

**Oleandrin**

**Lopinavir**

**Ritonavir**

**Hydroxychloroquine**

**Chloroquine**

**Azithromycin**

**Blood filtration**

**Fradulent**

**Bleach injections or ingestion**

**Sliver**

**UV light**


## Mechanism of action of antiviral drugs against SARS-CoV-2

Molnupiravir, AT-527 and remdesivir are all nucleoside analogues that are incorporated by the RNA-dependent RNA polymerase into the new RNA strand, ultimately halting further replication. PF-07321332 inhibits the protease enzyme responsible for cutting the long polypeptide strand into smaller, functional proteins that are needed for viral replication.

Vaccine induced antibodies to spike protein inhibit entry into cell. Antiviral ensovibep attaches similarly to 3 sites and prevents entry into cell


Treatment monoclonal antibodies are against spike protein

Regen-COV  
Bamlanivimab  
& Etesevimab  
Sotrovimab  
Evusheld




Paxlovid (PF-07321332) binds to 3C-like protease

## Nucleoside analogues interfere with polymerase function or induce fatal mutations





## Ensovibep binds spike protein at 3 sites




Much of damage by COVID is the body reaction in the form of cytokine storm

Drug approaches to controlling cytokine storm



Dexamethasone reduces transcription of inflammatory genes that can also have a detrimental effect on viral clearance by T-cells.



## **Update on masks**

**Because Omicron spreads so much more easily cloth masks are not effective  
The recommended masks are N95 or KN95**



# REASONS FOR GETTING A VACCINE

**Getting vaccinated is both common sense and a civic responsibility**

## PERSONAL

- **To avoid getting sick,**
- **To avoid being hospitalized**
- **To avoid ending up in Intensive Care, intubated.**
- **To avoid dying**
- **To avoid the disabling, long-COVID syndrome**
- **If you are pregnant, to protect the mother from severe, possibly fatal disease and to protect the baby, which could be lost**

## COMMUNITY

- **To spare overworked and stressed nurses and medical staff the burden of your care**
- **To limit your ability to spread a deadly infection to vulnerable people**
- **To protect your community**
- **To protect your family**
- **To protect your workplace**
- **To help control and limit this deadly pandemic.**

## WHAT A VACCINE DOES **NOT** DO

**Some myths debunked, and some solid science.**

- **No, there is no chip. (Why would anyone want to do this since you already have a cellphone???)**
- **No, it cannot magnetize you. You are not made of metal.**
- **No, it has no effect on fertility for men or women. Infection may.**
- **No, It does not lead to so called 'enhancement'. This is a rare phenomenon only so far associated with dengue virus, and not with any respiratory viruses, and only occurring in children.**
- **No, it cannot possibly cause COVID disease itself because it only contains a part of the virus, and not the internal mechanisms the virus uses to replicate itself.**
- **SARS type coronavirus pandemics depend on human behavior, not seasons.**
- **It does not induce 'enhancement' of other infectious diseases.**

# SO DO WE HAVE TO LEARN TO LIVE WITH CORONAVIRUSES?

**Probably Yes**

## WHAT DOES THIS MEAN?

- We **ALL** need to be vaccinated.
- Boosters or updated vaccines may become routine
- mRNA or protein vaccines with modified structures may be optimal
- For now, masks need to be universal in crowded and poorly ventilated places.
- Constant monitoring for new variants with flexible rapid responses.
- This is a global condition so:

**WE NEED LOW COST, STABLE VACCINES FOR THE ENTIRE WORLD AND WORK TO PREVENT THE CONDITIONS THAT FACILITATE THE EMERGENCE OF NEW VARIANTS.**